IXC - Invex TherapeuticsThis company is a Phase 3 ORPHAN bio focusing in on IIH.
They have 31 mill cash on hand which will fully fund them all the way. They are currently valued at 40 mill MC so essentially 9 mill EV which is ridiculous for a Phase 3 bio.
Putting in a bottoming pattern now with a reverse head and shoulders developing.
A break of 80 cents will be the trigger point, at the moment its just in accumulation phase still
